{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:24:39Z","timestamp":1787635479687,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    The purpose of the study is to evaluate the effects of 0.01% atropine eye drops on accommodative system parameters among teenagers with low myopia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Ninety-five myopic teenagers [39 boys (8.69 \u00b1 2.473) and 56 girls (8.54 \u00b1 2.054) aged 5\u201317\u00a0years] with no history of eye disease were enrolled. Biometric and accommodative system parameters were evaluated before and at 1\u00a0week, 1\u00a0month, 3\u00a0months, and 6\u00a0months of 0.01% atropine eye drop instillation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Participants without accommodative demand at 6\u00a0months demonstrated insignificant changes after the atropine instillation (all\n                    <jats:italic>p<\/jats:italic>\n                    &amp;gt; 0.05). Nevertheless, there were significant differences in accommodative sensitivity, accommodative amplitude, accommodative responsiveness, and negative relative accommodation (NRA) at 3\u00a0months compared with baseline after atropine instillation (all\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.05). Except spherical equivalent refraction, cornea thickness, intraocular pressure, and axial length were stable after the 0.01% atropine instillation (all\n                    <jats:italic>p<\/jats:italic>\n                    &amp;gt; 0.05).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Morphologically, current measurements suggested that 0.01% atropine had favorable reduction of accommodation for childhood low myopia over a half-year period.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.808440","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T03:14:51Z","timestamp":1644290091000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of 0.01% Atropine on Accommodation in Myopic Teenagers"],"prefix":"10.3389","volume":"13","author":[{"given":"Huixia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenping","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1136\/bjophthalmol-2019-314819","article-title":"Low-dose (0.01%) Atropine Eye-Drops to Reduce Progression of Myopia in Children: a Multicentre Placebo-Controlled Randomised Trial in the UK (CHAMP-UK)-study Protocol","volume":"104","author":"Azuara-Blanco","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3760\/cma.j.cn112142-20200622-00413","article-title":"The Safety of Atropine for Myopia Prevention and Control","volume":"57","author":"Chen","year":"2021","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e16434","DOI":"10.1097\/MD.0000000000016434","article-title":"Accommodation Changes after Visian Implantable Collamer Lens with central Hole for High Myopia: A STROBE-Compliant Article","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%","volume":"157","author":"Chia","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"18310","DOI":"10.1038\/s41598-020-75342-9","article-title":"Additive Effect of Atropine Eye Drops and Short-Term Retinal Defocus on Choroidal Thickness in Children with Myopia","volume":"10","author":"Chiang","year":"2020","journal-title":"Sci. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","article-title":"Efficacy and Safety of 0.01% Atropine for Prevention of Childhood Myopia in a 2-year Randomized Placebo-Controlled Study","volume":"65","author":"Hieda","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/eye.2013.256","article-title":"Myopia, an Underrated Global challenge to Vision: where the Current Data Takes Us on Myopia Control","volume":"28","author":"Holden","year":"2014","journal-title":"Eye (Lond)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.4103\/ijo.IJO_3028_20","article-title":"Commentary: Impact of the COVID-19 Pandemic on Digital Eye Strain in Children","volume":"68","author":"Jayadev","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","article-title":"Side Effects of Topical Atropine 0.05% Compared to 0.01% for Myopia Control in German School Children: a Pilot Study","volume":"41","author":"Joachimsen","year":"2021","journal-title":"Int. Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI Prevention of Myopia and its Progression","volume":"62","author":"Jonas","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1159\/000515755","article-title":"Effects of Single and Repeated Intravitreal Applications of Atropine on Choroidal Thickness in Alert Chickens","volume":"64","author":"Mathis","year":"2021","journal-title":"Ophthalmic Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia","volume":"379","author":"Morgan","year":"2012","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","article-title":"Atropine for the Prevention of Myopia Progression in Children: A Report by the American Academy of Ophthalmology","volume":"124","author":"Pineles","year":"2017","journal-title":"Ophthalmology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaapos.2020.11.003","article-title":"The Use of Atropine for Treatment of Amblyopia Using the OptumLabs Data Warehouse","volume":"25","author":"Pineles","year":"2021","journal-title":"J. AAPOS"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A 3-year Follow-Up Study of Atropine Treatment for Progressive Myopia in Europeans","volume":"34","author":"Polling","year":"2020","journal-title":"Eye (Lond)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/s0161-6420(01)00972-1","article-title":"Interventions to Retard Myopia Progression in Children: an Evidence-Based Update","volume":"109","author":"Saw","year":"2002","journal-title":"Ophthalmology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/nu13113790","article-title":"Validation of a Web-Based, Time-Use Application to Assess Children's School Meal Intakes: My E-Diary for Activities and Lifestyle (MEDAL)","volume":"13","author":"Tan","year":"2021","journal-title":"Nutrients"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11206721211053175","DOI":"10.1177\/11206721211053175","article-title":"COVID-19 Outbreak and Increased Risk of Amblyopia and Epidemic Myopia: Insights from EUROCOVCAT Group","author":"Toro","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/APO.0000000000000414","article-title":"A Meta-Analysis Assessing Change in Pupillary Diameter, Accommodative Amplitude, and Efficacy of Atropine for Myopia Control","author":"Tran","year":"2021","journal-title":"Asia Pac. J. Ophthalmol. (Phila)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173766","article-title":"Is 0.01% Atropine an Effective and Safe Treatment for Myopic Children? A Systemic Review and Meta-Analysis","volume":"10","author":"Tsai","year":"2021","journal-title":"J. Clin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"CD004916","DOI":"10.1002\/14651858.CD004916.pub4","article-title":"Interventions to Slow Progression of Myopia in Children","volume":"1","author":"Walline","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamaophthalmol.2020.6239","article-title":"Progression of Myopia in School-Aged Children after COVID-19 Home Confinement","volume":"139","author":"Wang","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1167\/iovs.17-23707","article-title":"Genipin-Crosslinked Donor Sclera for Posterior Scleral Contraction\/Reinforcement to Fight Progressive Myopia","volume":"59","author":"Xue","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cxo.13128","article-title":"Comparisons of Atropine versus Cyclopentolate Cycloplegia in Myopic Children","volume":"104","author":"Ye","year":"2021","journal-title":"Clin. Exp. Optom."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.808440\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T03:14:55Z","timestamp":1644290095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.808440\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":27,"alternative-id":["10.3389\/fphar.2022.808440"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.808440","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]},"article-number":"808440"}}